Skip to main content

Table 1 Patient characteristics

From: Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient

Patient characteristics

all

<65 years

≥ 65 years

Number of Patients

88

73

15

Median age (range), years

56 (32–78)

  
 

n (%)

  

Gender

 Female

31 (35.2)

29 (39.7)

2 (13.3)

 Male

57 (64.8)

44 (60.3)

13 (86.7)

ECOG PS

 0

49 (55.7)

43 (58.9)

6 (40.0)

 1

36 (40.9)

27 (37.0)

9 (60.0)

 2

3 (3.4)

3 (4.1)

0

Metastatic disease

79 (89.8)

64 (87.7)

15 (100.0)

Locally advanced tumor

9 (10.2)

9 (12.3)

0

Primary palliative treatment

66 (75.0)

55 (75.3)

11 (73.3)

Previous resection

22 (25.0)

18 (24.7)

4 (26.7)

 Prior (neo-) adjuvant CTX

13 (14.8)

11 (15.1)

2 (13.3)

Site of Tumor

 Pancreatic head

50 (56.8)

42 (57.5)

8 (53.3)

 Pancreatic corpus

22 (25.0)

20 (27.4)

2 (13.3)

 Pancreatic tail

16 (18.2)

11 (15.1)

5 (33.3)